A citation-based method for searching scientific literature

Megan J Bywater, Gretchen Poortinga, Elaine Sanij, Nadine Hein, Abigail Peck, Carleen Cullinane, Meaghan Wall, Leonie Cluse, Denis Drygin, Kenna Anderes, Nanni Huser, Chris Proffitt, Joshua Bliesath, Mustapha Haddach, Michael K Schwaebe, David M Ryckman, William G Rice, Clemens Schmitt, Scott W Lowe, Ricky W Johnstone, Richard B Pearson, Grant A McArthur, Ross D Hannan. Cancer Cell 2012
Times Cited: 373







List of co-cited articles
936 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Denis Drygin, Amy Lin, Josh Bliesath, Caroline B Ho, Sean E O'Brien, Chris Proffitt, Mayuko Omori, Mustapha Haddach, Michael K Schwaebe, Adam Siddiqui-Jain,[...]. Cancer Res 2011
354
48

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
Hong Xu, Marco Di Antonio, Steven McKinney, Veena Mathew, Brandon Ho, Nigel J O'Neil, Nancy Dos Santos, Jennifer Silvester, Vivien Wei, Jessica Garcia,[...]. Nat Commun 2017
257
35

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Amit Khot, Natalie Brajanovski, Donald P Cameron, Nadine Hein, Kylee H Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery,[...]. Cancer Discov 2019
72
43

Ribosome biogenesis in cancer: new players and therapeutic avenues.
Joffrey Pelletier, George Thomas, Siniša Volarević. Nat Rev Cancer 2018
299
25

A targeting modality for destruction of RNA polymerase I that possesses anticancer activity.
Karita Peltonen, Laureen Colis, Hester Liu, Rishi Trivedi, Michael S Moubarek, Henna M Moore, Baoyan Bai, Michelle A Rudek, Charles J Bieberich, Marikki Laiho. Cancer Cell 2014
166
24

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning.
Peter M Bruno, Mengrou Lu, Kady A Dennis, Haider Inam, Connor J Moore, John Sheehe, Stephen J Elledge, Michael T Hemann, Justin R Pritchard. Proc Natl Acad Sci U S A 2020
50
42

Chemotherapeutic drugs inhibit ribosome biogenesis at various levels.
Kaspar Burger, Bastian Mühl, Thomas Harasim, Michaela Rohrmoser, Anastassia Malamoussi, Mathias Orban, Markus Kellner, Anita Gruber-Eber, Elisabeth Kremmer, Michael Hölzel,[...]. J Biol Chem 2010
275
20

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova,[...]. Nat Commun 2020
54
37

Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age.
Rita Ferreira, John S Schneekloth, Konstantin I Panov, Katherine M Hannan, Ross D Hannan. Cells 2020
57
35

The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer.
Denis Drygin, William G Rice, Ingrid Grummt. Annu Rev Pharmacol Toxicol 2010
296
18

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
Jaclyn Quin, Keefe T Chan, Jennifer R Devlin, Donald P Cameron, Jeannine Diesch, Carleen Cullinane, Jessica Ahern, Amit Khot, Nadine Hein, Amee J George,[...]. Oncotarget 2016
62
29

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Denis Drygin, Adam Siddiqui-Jain, Sean O'Brien, Michael Schwaebe, Amy Lin, Josh Bliesath, Caroline B Ho, Chris Proffitt, Katy Trent, Jeffrey P Whitten,[...]. Cancer Res 2009
360
18

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.
Mustapha Haddach, Michael K Schwaebe, Jerome Michaux, Johnny Nagasawa, Sean E O'Brien, Jeffrey P Whitten, Fabrice Pierre, Pauline Kerdoncuff, Levan Darjania, Ryan Stansfield,[...]. ACS Med Chem Lett 2012
72
25

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
Peter M Bruno, Yunpeng Liu, Ga Young Park, Junko Murai, Catherine E Koch, Timothy J Eisen, Justin R Pritchard, Yves Pommier, Stephen J Lippard, Michael T Hemann. Nat Med 2017
224
17

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
Nadine Hein, Donald P Cameron, Katherine M Hannan, Nhu-Y N Nguyen, Chun Yew Fong, Jirawas Sornkom, Meaghan Wall, Megan Pavy, Carleen Cullinane, Jeannine Diesch,[...]. Blood 2017
44
36

The nucleolus under stress.
Séverine Boulon, Belinda J Westman, Saskia Hutten, François-Michel Boisvert, Angus I Lamond. Mol Cell 2010
641
16

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
Jennifer R Devlin, Katherine M Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J George, Jake Shortt, Megan J Bywater, Gretchen Poortinga,[...]. Cancer Discov 2016
82
19


MYC as a regulator of ribosome biogenesis and protein synthesis.
Jan van Riggelen, Alper Yetil, Dean W Felsher. Nat Rev Cancer 2010
547
14


Nucleolus as an emerging hub in maintenance of genome stability and cancer pathogenesis.
Mikael S Lindström, Deana Jurada, Sladana Bursac, Ines Orsolic, Jiri Bartek, Sinisa Volarevic. Oncogene 2018
102
12

Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
Robert Cornelison, Zachary C Dobbin, Ashwini A Katre, Dae Hoon Jeong, Yinfeng Zhang, Dongquan Chen, Yuliya Petrova, Danielle C Llaneza, Adam D Steg, Laura Parsons,[...]. Clin Cancer Res 2017
29
41

The nucleolus: an emerging target for cancer therapy.
Nadine Hein, Katherine M Hannan, Amee J George, Elaine Sanij, Ross D Hannan. Trends Mol Med 2013
148
12

What the nucleolus says to a tumour pathologist.
Massimo Derenzini, Lorenzo Montanaro, Davide Treré. Histopathology 2009
158
11

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
11

Does the ribosome translate cancer?
Davide Ruggero, Pier Paolo Pandolfi. Nat Rev Cancer 2003
729
11

CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma.
Leiming Li, Yan Li, Jiansong Zhao, Shuli Fan, Liguo Wang, Xu Li. Onco Targets Ther 2016
31
35

Nucleolus, ribosomes, and cancer.
Lorenzo Montanaro, Davide Treré, Massimo Derenzini. Am J Pathol 2008
302
10


The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Richard J Rebello, Eric Kusnadi, Donald P Cameron, Helen B Pearson, Analia Lesmana, Jennifer R Devlin, Denis Drygin, Ashlee K Clark, Laura Porter, John Pedersen,[...]. Clin Cancer Res 2016
47
21

Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint.
Ting Wei, Saman M Najmi, Hester Liu, Karita Peltonen, Alena Kucerova, David A Schneider, Marikki Laiho. Cell Rep 2018
33
30

p53 and ribosome biogenesis stress: the essentials.
Lior Golomb, Sinisa Volarevic, Moshe Oren. FEBS Lett 2014
149
10

Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress.
Sladana Bursać, Maja Cokarić Brdovčak, Martin Pfannkuchen, Ines Orsolić, Lior Golomb, Yan Zhu, Chen Katz, Lilyn Daftuar, Kristina Grabušić, Iva Vukelić,[...]. Proc Natl Acad Sci U S A 2012
139
10

Signaling to p53: ribosomal proteins find their way.
Yanping Zhang, Hua Lu. Cancer Cell 2009
414
10

The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability.
Jean-Clément Mars, Michel G Tremblay, Mélissa Valere, Dany S Sibai, Marianne Sabourin-Felix, Frédéric Lessard, Tom Moss. NAR Cancer 2020
17
58

Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.
Karita Peltonen, Laureen Colis, Hester Liu, Sari Jäämaa, Henna M Moore, Juulia Enbäck, Pirjo Laakkonen, Anne Vaahtokari, Richard J Jones, Taija M af Hällström,[...]. PLoS One 2010
67
13

Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency.
Maria Barna, Aya Pusic, Ornella Zollo, Maria Costa, Nadya Kondrashov, Eduardo Rego, Pulivarthi H Rao, Davide Ruggero. Nature 2008
294
9

Nucleolar stress with and without p53.
Allison James, Yubo Wang, Himanshu Raje, Raphyel Rosby, Patrick DiMario. Nucleus 2014
169
9

The 5S RNP couples p53 homeostasis to ribosome biogenesis and nucleolar stress.
Katherine E Sloan, Markus T Bohnsack, Nicholas J Watkins. Cell Rep 2013
179
9


The relationship between the nucleolus and cancer: Current evidence and emerging paradigms.
Ines Orsolic, Deana Jurada, Nick Pullen, Moshe Oren, Aristides G Eliopoulos, Sinisa Volarevic. Semin Cancer Biol 2016
89
10

Targeting the nucleolus for cancer intervention.
Jaclyn E Quin, Jennifer R Devlin, Donald Cameron, Kate M Hannan, Richard B Pearson, Ross D Hannan. Biochim Biophys Acta 2014
153
9


Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics.
Frédéric Catez, Nicole Dalla Venezia, Virginie Marcel, Christiane Zorbas, Denis L J Lafontaine, Jean-Jacques Diaz. Biochem Pharmacol 2019
65
13


Targeting RNA polymerase I to treat MYC-driven cancer.
G Poortinga, L M Quinn, R D Hannan. Oncogene 2015
60
13

Nucleolar function and size in cancer cells.
M Derenzini, D Trerè, A Pession, L Montanaro, V Sirri, R L Ochs. Am J Pathol 1998
158
8

Regulation of HDM2 activity by the ribosomal protein L11.
Marion A E Lohrum, Robert L Ludwig, Michael H G Kubbutat, Mary Hanlon, Karen H Vousden. Cancer Cell 2003
508
8

Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis.
Sladana Bursac, Maja Cokaric Brdovcak, Giulio Donati, Sinisa Volarevic. Biochim Biophys Acta 2014
102
8

The multifunctional nucleolus.
François-Michel Boisvert, Silvana van Koningsbruggen, Joaquín Navascués, Angus I Lamond. Nat Rev Mol Cell Biol 2007
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.